An International, Randomised, Double-Blind, Two-Arm Study To Evaluate The Safety And Efficacy Of Vandetanib 150 And 300mg/Day In Patients With Unresectable Locally Advanced Or Metastatic Medullary Thyroid Carcinoma With Progressive Or Symptomatic Disease.
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 16 Nov 2016
At a glance
- Drugs Vandetanib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- Sponsors AstraZeneca; Sanofi Genzyme
- 11 Nov 2016 Planned End Date changed from 1 Jun 2016 to 1 Dec 2019.
- 05 May 2016 Planned End Date changed from 1 Mar 2015 to 1 Jun 2016.
- 05 May 2016 Status changed from completed to active, no longer recruiting.